[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PickingMyOwn Panther

Panther posts on X about $abvx, $capr, $nktr, environment the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

• X Week XXXXXX +112%
• X Month XXXXXX -XXXX%
• X Months XXXXXXX +84%
• X Year XXXXXXX +120%

Mentions: X #

• X Week XX +23%
• X Month XX -XX%
• X Months XXX +4%
• X Year XXX +50%

Followers: XXX #

• X Week XXX +2%
• X Month XXX +5.20%
• X Months XXX +50%
• X Year XXX +97%

CreatorRank: undefined #

Social Influence

Social category influence finance XXXXX% stocks XXXX%

Social topic influence $abvx #35, $capr #5, $nktr 12.5%, environment 6.25%, acquisition 6.25%, target 6.25%, $abbv 6.25%, lack of 6.25%, $mreo 6.25%, $11b XXXX%

Top accounts mentioned or mentioned by @amaymd @tallnfat @houndcl @biobucks33 @wallstsai @charle77238 @andreagtc @mroliverbarnes @cpoption @rxgongivit2ya @bioluck80 @bronxb_13 @thebiotechbear @walterscottfund

Top assets mentioned AbbVie Inc (ABBV)

Top Social Posts

Top posts by engagements in the last XX hours

"@tallnfat @charle77238 $ABVX I dont think so but you should sell and come back in 6mo. In a competitive buying environment bidders cant wait. Thats a guarantee loss of acquiring. Obefazimod is the absolute best acquisition target in bio right now. Nobodys waiting. But again you do you"
X Link 2025-12-12T13:11Z XXX followers, XXX engagements

"@A_May_MD @houndcl @BioBucks33 $ABVX"
X Link 2025-12-03T23:34Z XXX followers, XXX engagements

"@A_May_MD @houndcl @BioBucks33 Thought about it overnight. $ABBV going after Obefazimod in such a helpless manner tells me they realize the asset is close to going into capable hands from a marketing and distribution standpoint. Otherwise silence is more prudent. $ABVX"
X Link 2025-12-04T14:22Z XXX followers, XXX engagements

"$CAPR joins the high probability buyout candidates $NKTR and $ABVX IMO. $XX to $70"
X Link 2025-12-08T16:12Z XXX followers, 5124 engagements

"@WallStSai $ABVX hottest commodity in biotech. Bidding war likely to end well above $200"
X Link 2025-12-09T15:10Z XXX followers, 1000 engagements

"@rxgongivit2ya Emil believes the lack of density intensifies fracture rates in common movements. Well see. The ph2b results make that case but in small sample size. $MREO"
X Link 2025-12-11T15:19Z XXX followers, XXX engagements

"$ABVX raised at $XX after data. You could have bought. $NKTR raised after data at $XX you could have bought. $CAPR raised after data at $XX. Just saying"
X Link 2025-12-12T14:47Z XXX followers, 3443 engagements

"A little more on $CAPR FDA Approval mid XX launch of Deramiocel in XX. By 2031 projected annual revenue $1.1B with a guess profit margin of XX% on 52M shares = $XXXXX EPS with a 12X multiple = $XXX PPS. Just saying. It derisked and going to be SOC"
X Link 2025-12-12T15:19Z XXX followers, XXX engagements